Implant Files

The US agency wants stakeholders to chime in on what information should be included in product labels to notify patients about potential side-effects of medical device materials, without being too burdensome for manufacturers.

Bayer launches multi-year campaign “Outsideologist Project” for Claritin to offer parents fun ways to get their children outside. GSK’s “Change the Game” campaign for Flonase as official allergy relief partner of MLB has new spokesman.

National Center for Health Research president Diana Zuckerman is concerned about a new joint notice from the US HHS and the FDA designed to deregulate a slew of devices and tests.

As expected based on retrospective data, new results from an ongoing postmarket study has found Bayer’s Essure birth control device has significantly higher rates of major adverse events compared to women who undergo tubal ligation.

While the Trump administration’s proposed fiscal year 2021 budget for the US FDA would give the agency’s device center a 5.3% increase for medtech product approvals and safety, the center’s lofty plans to become the world’s premier regulator of new AI-driven gadgets, next-gen diagnostics and other novel devices means it will have to tap about $2.8m dollars usually set aside for staff training and outreach to help meet its ambitious goals.

Following closely on the heels of a medical device tax repeal win, AdvaMed CEO Scott Whitaker sat down with Medtech Insight to discuss how the industry advocacy group ended the Obamacare excise tax and what it has in store for 2020.

The Therapeutic Goods Administration says it now has enough evidence to warrant cancelling, suspending and recalling a number of textured breast implants because of the potential risks of developing anaplastic large cell lymphoma.

March 2019 was a busy month in terms of news for those preparing for the implementation of the MDR and IVDR, while Brexit negotiations spiraled into a new level of madness.

Passing the half-way mark in the transition period to full implementation of the EU's new Medical Device Regulation (MDR) seems to have focused the attention of readers back onto technical regulatory issues.

Weeks after the "Implant Files" journalistic investigation of the device industry was released, EU industry advocate Serge Bernasconi described the results as "unhelpful" and "imbalanced." But might they also be disruptive, threatening the smooth rollout of new EU regulations? We put this and other questions to Bernasconi, chief executive of the EU's largest medtech trade association, MedTech Europe.